|
US6300361B1
(en)
*
|
1990-07-25 |
2001-10-09 |
Novartis Ag |
Stabilized pharmaceutical compositions comprising acid donors
|
|
DE4243279A1
(de)
*
|
1992-12-21 |
1994-06-23 |
Bayer Ag |
Substituierte Triole
|
|
US5399356A
(en)
*
|
1994-03-24 |
1995-03-21 |
The Procter & Gamble Company |
Process for making solid dose forms containing bismuth
|
|
JPH11512927A
(ja)
|
1995-08-17 |
1999-11-09 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
コレステロール合成を制御する遺伝子およびタンパク質
|
|
PL186907B1
(pl)
*
|
1995-12-22 |
2004-03-31 |
Kowa Co |
Kompozycja farmaceutyczna stabilizowana czynnikiem zasadowym
|
|
WO1997037688A2
(en)
*
|
1996-04-05 |
1997-10-16 |
Takeda Chemical Industries, Ltd. |
Pharmaceutical combination containing a compound having angiotensin ii and antagonistic activity
|
|
DE69705516T3
(de)
*
|
1996-04-16 |
2004-09-30 |
Takeda Chemical Industries, Ltd. |
D-mannit und seine herstellung
|
|
EP0907639B1
(en)
*
|
1996-06-24 |
2003-03-12 |
Novartis AG |
Polymorphic compounds
|
|
SE9603667D0
(sv)
*
|
1996-10-08 |
1996-10-08 |
Astra Ab |
Pharmaceutical compositions
|
|
SE9603668D0
(sv)
*
|
1996-10-08 |
1996-10-08 |
Astra Ab |
Pharmaceutical compositions
|
|
DE19725391A1
(de)
*
|
1997-06-16 |
1998-12-17 |
Bayer Ag |
Verfahren zur Herstellung von Arzneimittel, enthaltend HMG-CoA-Reduktase-Inhibitoren
|
|
US6465477B1
(en)
*
|
1997-08-18 |
2002-10-15 |
Kowa Company, Ltd. |
Stable pharmaceutical composition
|
|
US20060141036A1
(en)
*
|
1997-12-12 |
2006-06-29 |
Andrx Labs Llc |
HMG-CoA reductase inhibitor extended release formulation
|
|
US6235311B1
(en)
*
|
1998-03-18 |
2001-05-22 |
Bristol-Myers Squibb Company |
Pharmaceutical composition containing a combination of a statin and aspirin and method
|
|
US20010014352A1
(en)
|
1998-05-27 |
2001-08-16 |
Udit Batra |
Compressed tablet formulation
|
|
US5997905A
(en)
*
|
1998-09-04 |
1999-12-07 |
Mcneil-Ppc |
Preparation of pharmaceutically active particles
|
|
SI20070A
(sl)
*
|
1998-09-18 |
2000-04-30 |
LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. |
Nove soli inhibitorjev HMG-CoA reduktaze
|
|
US20020169145A1
(en)
*
|
1998-10-14 |
2002-11-14 |
Rajen Shah |
Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent
|
|
NZ511792A
(en)
|
1998-11-20 |
2003-08-29 |
Skyepharma Canada Inc |
Dispersible phospholipid stabilized microparticles
|
|
TWI230618B
(en)
*
|
1998-12-15 |
2005-04-11 |
Gilead Sciences Inc |
Pharmaceutical compositions of 9-[2-[[bis[(pivaloyloxy)methyl]phosphono]methoxy]ethyl]adenine and tablets or capsules containing the same
|
|
SI20109A
(sl)
*
|
1998-12-16 |
2000-06-30 |
LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. |
Stabilna farmacevtska formulacija
|
|
EP1036563A1
(en)
*
|
1999-03-08 |
2000-09-20 |
MERCK & CO. INC. |
Delayed-release oral formulation of dihydroxy open acid simvastatin and salts and esters thereof
|
|
US6569461B1
(en)
|
1999-03-08 |
2003-05-27 |
Merck & Co., Inc. |
Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors
|
|
CA2364253A1
(en)
*
|
1999-03-08 |
2000-09-14 |
Merck & Co., Inc. |
Dihydroxy open-acid and salts of hmg-co-a reductase inhibitors
|
|
AU4988100A
(en)
*
|
1999-05-07 |
2000-11-21 |
Brigham And Women's Hospital |
Use of hmgcoa reductase inhibitors in the prevention of diseases whose pathogenesis is dependent on neovascularization
|
|
US20020107173A1
(en)
*
|
1999-11-04 |
2002-08-08 |
Lawrence Friedhoff |
Method of treating amyloid beta precursor disorders
|
|
JP2003523948A
(ja)
*
|
1999-11-04 |
2003-08-12 |
アンドルクス コーポレーション |
アミロイドβ前駆体障害の治療法
|
|
GB0001621D0
(en)
*
|
2000-01-26 |
2000-03-15 |
Astrazeneca Ab |
Pharmaceutical compositions
|
|
EP1267914B2
(en)
|
2000-02-04 |
2013-11-06 |
Children's Hospital Research Foundation |
Use of lysosomal acid lipase for treating atherosclerosis and related diseases
|
|
WO2001076598A1
(fr)
*
|
2000-04-11 |
2001-10-18 |
Sankyo Company, Limited |
Compositions pharmaceutiques stabilisees contenant des bloqueurs des canaux calcium
|
|
US6242003B1
(en)
|
2000-04-13 |
2001-06-05 |
Novartis Ag |
Organic compounds
|
|
GB0011163D0
(en)
*
|
2000-05-10 |
2000-06-28 |
Astrazeneca Ab |
Chemical compound
|
|
IL152580A0
(en)
*
|
2000-05-26 |
2003-05-29 |
Ciba Sc Holding Ag |
Process for the preparation of indole derivatives and intermediates of the process
|
|
CA2412326A1
(en)
|
2000-06-09 |
2001-12-13 |
Lek Pharmaceuticals D.D. |
Stabilized hmg-coa reductase inhibitor pharmaceutical compositions
|
|
ATE418979T2
(de)
|
2000-06-09 |
2009-01-15 |
Lek Pharmaceuticals |
Stabilisiertes arzneimittel und arzneizubereitung
|
|
US6806290B2
(en)
|
2000-06-09 |
2004-10-19 |
Lek Pharmaceuticals D.D. |
Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same
|
|
US8586094B2
(en)
|
2000-09-20 |
2013-11-19 |
Jagotec Ag |
Coated tablets
|
|
US7407484B2
(en)
|
2001-04-06 |
2008-08-05 |
Medic4All Inc. |
Physiological monitoring system for a computational device of a human subject
|
|
US20060127474A1
(en)
|
2001-04-11 |
2006-06-15 |
Oskar Kalb |
Pharmaceutical compositions comprising fluvastatin
|
|
GB0111077D0
(en)
|
2001-05-04 |
2001-06-27 |
Biochemie Gmbh |
Organic compounds
|
|
US6699886B2
(en)
*
|
2001-05-31 |
2004-03-02 |
Cellegy Pharmaceuticals, Inc. |
Store operated calcium influx inhibitors and methods of use
|
|
CA2450001A1
(en)
*
|
2001-06-21 |
2003-01-03 |
Andrx Pharmaceuticals, Inc. |
Stable pharmaceutical compositions containing pravastatin
|
|
WO2003032921A2
(en)
|
2001-10-16 |
2003-04-24 |
Sloan-Kettering Institute For Cancer Research |
Treatment of neurodegenerative diseases and cancer of the brain
|
|
US7183321B2
(en)
*
|
2001-12-17 |
2007-02-27 |
Bristol-Myers Squibb Company |
Antidiabetic formulation and method
|
|
AR038839A1
(es)
*
|
2002-02-14 |
2005-01-26 |
Ranbaxy Lab Ltd |
Formulacion de atorvastatina estabilizada con aditamentos de metales alcalinos. metodo para su elaboracion
|
|
US7148257B2
(en)
|
2002-03-04 |
2006-12-12 |
Merck Hdac Research, Llc |
Methods of treating mesothelioma with suberoylanilide hydroxamic acid
|
|
US7456219B2
(en)
|
2002-03-04 |
2008-11-25 |
Merck Hdac Research, Llc |
Polymorphs of suberoylanilide hydroxamic acid
|
|
MXPA04008577A
(es)
|
2002-03-04 |
2005-07-13 |
Aton Pharma Inc |
Metodos para inducir diferenciacion terminal.
|
|
AU2003226051A1
(en)
*
|
2002-04-16 |
2003-11-03 |
Banyu Pharmaceutical Co., Ltd. |
Solid forms of salts with tyrosine kinase activity
|
|
DK3072978T3
(en)
|
2002-05-09 |
2018-09-17 |
Brigham & Womens Hospital Inc |
: 1L1RL-1 AS A CARDIOVASCULAR DISEASE MARKER
|
|
CA2385529A1
(en)
*
|
2002-05-21 |
2003-11-21 |
Bernard Charles Sherman |
Stable dosage forms comprising atorvastatin calcium
|
|
PT1515717E
(pt)
*
|
2002-06-13 |
2009-02-20 |
Novartis Ag |
Sais de cálcio de estatinas derivadas de indole
|
|
US20040006109A1
(en)
*
|
2002-07-03 |
2004-01-08 |
Rajneesh Taneja |
Liquid dosage forms of non-enterically coated acid-labile drugs
|
|
US20060019269A1
(en)
*
|
2002-10-17 |
2006-01-26 |
Decode Genetics, Inc. |
Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment
|
|
US20080293750A1
(en)
*
|
2002-10-17 |
2008-11-27 |
Anna Helgadottir |
Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment
|
|
US20040198800A1
(en)
*
|
2002-12-19 |
2004-10-07 |
Geoffrey Allan |
Lipoxygenase inhibitors as hypolipidemic and anti-hypertensive agents
|
|
CA2508840A1
(en)
|
2002-12-20 |
2004-07-08 |
Pfizer Products Inc. |
Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor
|
|
EP1585500B8
(en)
|
2002-12-20 |
2017-07-26 |
Auritec Pharmaceuticals |
Coated particles for sustained-release pharmaceutical administration
|
|
US20040132771A1
(en)
*
|
2002-12-20 |
2004-07-08 |
Pfizer Inc |
Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
|
|
KR20050110017A
(ko)
*
|
2003-03-17 |
2005-11-22 |
니뽄 다바코 산교 가부시키가이샤 |
Ｓ-'２-(''１-(２-에틸부틸)시클로헥실!카르보닐!아미노)페닐!-２-메틸프로판티오에이트의 경구 생체이용율을증가시키는 방법
|
|
TWI393560B
(zh)
*
|
2003-05-02 |
2013-04-21 |
Japan Tobacco Inc |
包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
|
|
US7166638B2
(en)
*
|
2003-05-27 |
2007-01-23 |
Nicox S.A. |
Statin derivatives
|
|
MXPA05012900A
(es)
|
2003-05-30 |
2006-02-22 |
Ranbaxy Lab Ltd |
Derivados de pirrol sustituidos.
|
|
EP1790634A3
(en)
*
|
2003-06-18 |
2007-06-13 |
Teva Pharmaceutical Industries Ltd. |
Fluvastatin sodium crystal form and processes for preparing it
|
|
RU2361582C2
(ru)
*
|
2003-06-25 |
2009-07-20 |
Новартис Аг |
Таблетка, содержащая флувастатин и кармеллозу кальция
|
|
JP2007077174A
(ja)
*
|
2003-06-25 |
2007-03-29 |
Novartis Ag |
フルバスタチン含有錠剤
|
|
GB2404336A
(en)
*
|
2003-07-30 |
2005-02-02 |
Cipla Ltd |
Stabilisation of therapeutic agents using a carbonate salt of an amino acid, preferably in the presence of a saccharide, & pharmaceutical compositions thereof
|
|
AU2004266740B2
(en)
|
2003-08-21 |
2010-08-26 |
Merck Frosst Canada Ltd |
Cathepsin cysteine protease inhibitors
|
|
EP1510208A1
(en)
|
2003-08-22 |
2005-03-02 |
Fournier Laboratories Ireland Limited |
Pharmaceutical composition comprising a combination of metformin and statin
|
|
KR20060109926A
(ko)
|
2003-11-19 |
2006-10-23 |
메타베이시스 테라퓨틱스, 인크. |
새로운 인-함유 갑상선 호르몬 모방약들
|
|
EP1722780A4
(en)
*
|
2003-11-26 |
2008-12-17 |
Univ Duke |
METHOD FOR PREVENTING OR TREATING GLAUCOMA
|
|
ATE535614T1
(de)
|
2003-12-30 |
2011-12-15 |
Kowa Co |
Screening-verfahren fuer gamma-sekretase- inhibitoren
|
|
US8163797B2
(en)
*
|
2003-12-31 |
2012-04-24 |
Actavis Elizabeth Llc |
Method of treating with stable pravastatin formulation
|
|
US8158362B2
(en)
*
|
2005-03-30 |
2012-04-17 |
Decode Genetics Ehf. |
Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype
|
|
US20100216863A1
(en)
*
|
2004-01-30 |
2010-08-26 |
Decode Genetics Ehf. |
Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment
|
|
US7803838B2
(en)
*
|
2004-06-04 |
2010-09-28 |
Forest Laboratories Holdings Limited |
Compositions comprising nebivolol
|
|
MX2007001558A
(es)
*
|
2004-08-06 |
2008-03-13 |
Transform Pharmaceuticals Inc |
Formulaciones novedosas de fenofibrato y metodos de tratamiento relacionados.
|
|
US20090042979A1
(en)
*
|
2004-08-06 |
2009-02-12 |
Transform Pharmaceuticals Inc. |
Novel Statin Pharmaceutical Compositions and Related Methods of Treatment
|
|
BRPI0514189A
(pt)
*
|
2004-08-06 |
2008-06-03 |
Transform Pharmaceuticals Inc |
composições farmacêuticas de estatina e métodos de tratamento relacionados
|
|
DE102004042139B4
(de)
*
|
2004-08-31 |
2009-06-10 |
Aristocon Verwaltungs- Gmbh |
Perorale Darreichungsformen zur Erzielung eines Retardierungseffektes nach der Arzneimitteleinnahme mit einer Mahlzeit
|
|
US9164104B2
(en)
|
2004-10-06 |
2015-10-20 |
The Brigham And Women's Hospital, Inc. |
Relevance of achieved levels of markers of systemic inflammation following treatment
|
|
ES2255426B1
(es)
|
2004-10-19 |
2007-08-16 |
Gp Pharm, S.A. |
Formulacion farmaceutica que comprende microcapsulas de estatinas suspendidas en ester alquilicos de acidos grasos poliinsaturados (pufa).
|
|
EP1827421B1
(en)
|
2004-12-09 |
2017-09-27 |
Merck Sharp & Dohme Corp. |
Estrogen receptor modulators
|
|
NZ555693A
(en)
|
2004-12-27 |
2010-10-29 |
Eisai R&D Man Co Ltd |
Matrix type sustained-release preparation containing donepezil
|
|
US20070129402A1
(en)
*
|
2004-12-27 |
2007-06-07 |
Eisai Research Institute |
Sustained release formulations
|
|
SG175477A1
(en)
*
|
2005-01-31 |
2011-11-28 |
Mylan Lab Inc |
Hydroxylated nebivolol metabolites
|
|
JP2008531691A
(ja)
|
2005-03-02 |
2008-08-14 |
メルク エンド カムパニー インコーポレーテッド |
カテプシンｋ阻害組成物
|
|
US20060229277A1
(en)
*
|
2005-04-08 |
2006-10-12 |
Orbus Pharma, Inc. |
Stabilized pharmaceutical compositions comprising an HMG-CoA reductase inhibitor
|
|
JP5597343B2
(ja)
*
|
2005-04-28 |
2014-10-01 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
抗痴呆薬を含有する組成物
|
|
ATE550019T1
(de)
|
2005-05-17 |
2012-04-15 |
Merck Sharp & Dohme |
Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs
|
|
NZ563759A
(en)
|
2005-05-31 |
2010-06-25 |
Mylan Lab Inc |
Compositions comprising nebivolol, a hydralazine compound and an isosorbide nitrate
|
|
AU2006329564A1
(en)
|
2005-07-11 |
2007-07-05 |
Pharmena North America Inc. |
Formulations for treatment of lipoprotein abnormalities comprising a statin a statin and a methylnicotinamide derivative
|
|
EP1940391A4
(en)
*
|
2005-08-05 |
2010-01-20 |
Orbus Pharma Inc |
STABILIZED PHARMACEUTICAL COMPOSITIONS WITH EXTENDED RELEASE WITH AN HMG COA REDUCTASE INHIBITOR
|
|
TW200804345A
(en)
|
2005-08-30 |
2008-01-16 |
Novartis Ag |
Substituted benzimidazoles and methods of preparation
|
|
US8119358B2
(en)
|
2005-10-11 |
2012-02-21 |
Tethys Bioscience, Inc. |
Diabetes-related biomarkers and methods of use thereof
|
|
AU2006313430B2
(en)
|
2005-11-08 |
2012-09-06 |
Ranbaxy Laboratories Limited |
Process for (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
|
|
US20090247603A1
(en)
*
|
2005-12-23 |
2009-10-01 |
Orbus Pharma, Inc. |
Stabilized pharmaceutical compositions comprising an HMG-CoA reductase inhibitor
|
|
EP1905424A3
(en)
*
|
2006-02-02 |
2008-04-30 |
Ranbaxy Laboratories Limited |
Process for the preparation of a pharmaceutical composition comprising stabilized statin particles
|
|
GB0603041D0
(en)
|
2006-02-15 |
2006-03-29 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
|
JP2009527577A
(ja)
*
|
2006-02-24 |
2009-07-30 |
テバ ファーマシューティカル インダストリーズ リミティド |
フルバスタチンナトリウム医薬組成物
|
|
CL2007000667A1
(es)
*
|
2006-03-14 |
2008-03-14 |
Ranbaxi Lab Ltd |
Composicion farmaceutica que comprende al acido 7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroximetilfenilamino)carbonil]pirrol-1-il]-3,5-dihidroxi-heptanoico o una sal y al menos un agente estabilizante; procedimiento de preparacion, util en e
|
|
CA2649288C
(en)
|
2006-04-19 |
2015-11-24 |
Novartis Ag |
6-o-substituted benzoxazole and benzothiazole compounds and methods of inhibiting csf-1r signaling
|
|
EP2030025A2
(en)
|
2006-06-07 |
2009-03-04 |
Tethys Bioscience, Inc. |
Markers associated with arteriovascular events and methods of use thereof
|
|
AU2007265475B2
(en)
|
2006-06-26 |
2010-08-19 |
Amgen Inc. |
Methods for treating atherosclerosis
|
|
ES2532595T3
(es)
|
2006-08-30 |
2015-03-30 |
Kyushu University, National University Corporation |
Composición farmacéutica que contiene una nanopartícula de estatina encapsulada
|
|
WO2008039327A2
(en)
|
2006-09-22 |
2008-04-03 |
Merck & Co., Inc. |
Method of treatment using fatty acid synthesis inhibitors
|
|
KR101884047B1
(ko)
*
|
2006-09-26 |
2018-07-31 |
노파르티스 아게 |
Ｓ１ｐ 조정제를 포함하는 제약 조성물
|
|
EP1923053A1
(en)
*
|
2006-09-27 |
2008-05-21 |
Novartis AG |
Pharmaceutical compositions comprising nilotinib or its salt
|
|
EP1911441A3
(en)
*
|
2006-10-11 |
2008-08-06 |
Lupin Limited |
Controlled release color stable pharmaceutical dosage form of HMG-COA reductase inhibitors, free of alkalizing or buffering agents
|
|
US20110218176A1
(en)
|
2006-11-01 |
2011-09-08 |
Barbara Brooke Jennings-Spring |
Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
|
|
US20110052688A1
(en)
*
|
2006-11-21 |
2011-03-03 |
San-Laung Chow |
Solid dispersion composition
|
|
WO2008064259A2
(en)
*
|
2006-11-21 |
2008-05-29 |
Biokey, Inc. |
Solid dispersion composition comprising fluvastatin
|
|
KR101591656B1
(ko)
|
2007-01-10 |
2016-02-19 |
엠에스디 이탈리아 에스.알.엘. |
폴리(ａｄｐ-리보오스) 폴리머라아제(ｐａｒｐ) 억제제로서의 아미드 치환된 인다졸
|
|
WO2008106692A1
(en)
|
2007-03-01 |
2008-09-04 |
Novartis Vaccines And Diagnostics, Inc. |
Pim kinase inhibitors and methods of their use
|
|
WO2008124121A1
(en)
*
|
2007-04-06 |
2008-10-16 |
Scidose, Llc |
Co-therapy with and combinations of statins and 1,4-dihydropyridine-3,5-dicarboxydiesters
|
|
KR20090127904A
(ko)
*
|
2007-04-09 |
2009-12-14 |
싸이도우스 엘엘씨. |
스타틴과 항비만제의 복합물
|
|
US20080249156A1
(en)
*
|
2007-04-09 |
2008-10-09 |
Palepu Nageswara R |
Combinations of statins and anti-obesity agent and glitazones
|
|
EP2541254B1
(en)
|
2007-04-18 |
2014-11-12 |
Health Diagnostic Laboratory, Inc. |
Diabetes-related biomarkers and methods of use thereof
|
|
BRPI0812159A2
(pt)
|
2007-05-21 |
2017-05-02 |
Novartis Ag |
inibidores de csf-1r, composições e métodos de uso
|
|
WO2009002495A1
(en)
|
2007-06-27 |
2008-12-31 |
Merck & Co., Inc. |
4-carboxybenzylamino derivatives as histone deacetylase inhibitors
|
|
UA103304C2
(ru)
|
2007-07-26 |
2013-10-10 |
Эмджен Инк. |
Модифицированный белок лецитин-холестерин ацилтрансферазы (lcat)
|
|
US8354446B2
(en)
|
2007-12-21 |
2013-01-15 |
Ligand Pharmaceuticals Incorporated |
Selective androgen receptor modulators (SARMs) and uses thereof
|
|
DK2306982T3
(en)
*
|
2008-06-27 |
2015-04-20 |
Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi |
Pharmaceutical compositions of rosuvastatin calcium
|
|
EP2138165A1
(en)
|
2008-06-27 |
2009-12-30 |
KRKA, tovarna zdravil, d.d., Novo mesto |
Pharmaceutical composition comprising a statin
|
|
ES2657416T3
(es)
*
|
2008-06-27 |
2018-03-05 |
Krka, Torvarna Zdravil, D.D., Novo Mesto |
Composición farmacéutica que comprende una estatina
|
|
US20120046364A1
(en)
|
2009-02-10 |
2012-02-23 |
Metabasis Therapeutics, Inc. |
Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use
|
|
JP2012096998A
(ja)
*
|
2009-02-27 |
2012-05-24 |
Kowa Co |
安定なカプセル製剤及びその製造方法
|
|
US8691825B2
(en)
|
2009-04-01 |
2014-04-08 |
Merck Sharp & Dohme Corp. |
Inhibitors of AKT activity
|
|
TR200904341A2
(tr)
|
2009-06-03 |
2010-12-21 |
Bi̇lgi̇ç Mahmut |
Rosuvastatin kalsiyum içeren kararlı farmasötik bileşimler.
|
|
WO2011046771A1
(en)
|
2009-10-14 |
2011-04-21 |
Schering Corporation |
SUBSTITUTED PIPERIDINES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF
|
|
EP2515943A4
(en)
*
|
2009-12-22 |
2014-04-30 |
Fmc Corp |
MICROCRYSTALLINE CELLULOSE AND CALCIUM CARBONATE COMPOSITIONS USEFUL AS RECOMPACTABLE PHARMACEUTICAL EXCIPIENTS
|
|
KR20120139723A
(ko)
|
2010-02-01 |
2012-12-27 |
더 호스피탈 포 식 칠드런 |
재발협착증의 치료 및 예방을 위한 원격 허혈 처치
|
|
CA2795053A1
(en)
|
2010-03-31 |
2011-10-06 |
The Hospital For Sick Children |
Use of remote ischemic conditioning to improve outcome after myocardial infarction
|
|
EP2555692A2
(en)
|
2010-04-08 |
2013-02-13 |
The Hospital For Sick Children |
Use of remote ischemic conditioning for traumatic injury
|
|
US8372877B2
(en)
|
2010-04-16 |
2013-02-12 |
Cumberland Pharmaceuticals |
Stabilized statin formulations
|
|
TR201009397A2
(tr)
|
2010-11-11 |
2012-05-21 |
Bi̇lgi̇ç Mahmut |
Rosuvastatin içeren farmasötik bileşimler.
|
|
EP2584903B1
(en)
|
2010-06-24 |
2018-10-24 |
Merck Sharp & Dohme Corp. |
Novel heterocyclic compounds as erk inhibitors
|
|
CA2803558C
(en)
*
|
2010-06-30 |
2018-05-29 |
Mochida Pharmaceutical Co., Ltd. |
.omega.3 fatty acid compound preparation
|
|
EP3330377A1
(en)
|
2010-08-02 |
2018-06-06 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)
|
|
PL2600850T3
(pl)
|
2010-08-04 |
2019-06-28 |
Grünenthal GmbH |
Farmaceutyczna postać dawkowania zawierająca 6'-fluoro-(n-metylo- lub n,n-dimetylo-)-4-fenylo-4',9'-dihydro-3'h-spiro[cykloheksano-1,1'-pirano[3,4,b]indolo]-4-aminę do leczenia bólu nocyceptywnego
|
|
CN108676800B
(zh)
|
2010-08-17 |
2022-11-11 |
瑟纳治疗公司 |
使用短干扰核酸(siNA)的乙型肝炎病毒(HBV)基因表达的RNA干扰介导的抑制
|
|
US8883801B2
(en)
|
2010-08-23 |
2014-11-11 |
Merck Sharp & Dohme Corp. |
Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
|
|
WO2012027331A1
(en)
|
2010-08-27 |
2012-03-01 |
Ironwood Pharmaceuticals, Inc. |
Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
|
|
EP2613782B1
(en)
|
2010-09-01 |
2016-11-02 |
Merck Sharp & Dohme Corp. |
Indazole derivatives useful as erk inhibitors
|
|
WO2012036997A1
(en)
|
2010-09-16 |
2012-03-22 |
Schering Corporation |
Fused pyrazole derivatives as novel erk inhibitors
|
|
EP2626069A4
(en)
|
2010-10-06 |
2014-03-19 |
Univ Tokyo |
Prophylactic and/or therapeutic agent against lymphedema
|
|
DK2632472T3
(en)
|
2010-10-29 |
2018-03-19 |
Sirna Therapeutics Inc |
RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA)
|
|
EP2654748B1
(en)
|
2010-12-21 |
2016-07-27 |
Merck Sharp & Dohme Corp. |
Indazole derivatives useful as erk inhibitors
|
|
US8791162B2
(en)
|
2011-02-14 |
2014-07-29 |
Merck Sharp & Dohme Corp. |
Cathepsin cysteine protease inhibitors
|
|
WO2012141160A1
(ja)
|
2011-04-12 |
2012-10-18 |
沢井製薬株式会社 |
ピタバスタチン含有製剤及びその製造方法
|
|
CN103732592A
(zh)
|
2011-04-21 |
2014-04-16 |
默沙东公司 |
胰岛素样生长因子-1受体抑制剂
|
|
WO2012153181A1
(en)
*
|
2011-05-11 |
2012-11-15 |
Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi |
Pharmaceutical composition comprising pitavastatin or its pharmaceutically acceptable salts
|
|
KR101830977B1
(ko)
*
|
2011-06-30 |
2018-02-21 |
한미약품 주식회사 |
오메가-3 지방산 또는 이의 에스테르 및 하이드록시메틸글루타닐 코엔자임에이 환원효소 억제제를 포함하는 경구용 복합 제제
|
|
US9023865B2
(en)
|
2011-10-27 |
2015-05-05 |
Merck Sharp & Dohme Corp. |
Compounds that are ERK inhibitors
|
|
TW201329104A
(zh)
|
2011-12-08 |
2013-07-16 |
Amgen Inc |
人類ｌｃａｔ抗原結合蛋白質及其治療用途
|
|
EP2844261B1
(en)
|
2012-05-02 |
2018-10-17 |
Sirna Therapeutics, Inc. |
SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
|
|
WO2014022195A1
(en)
|
2012-08-01 |
2014-02-06 |
Tavakoli Zahra |
Free flowing, frozen compositions comprising a therapeutic agent
|
|
EP3269362A1
(en)
|
2012-08-08 |
2018-01-17 |
KOWA Co., Ltd. |
Pharmaceutical composition comprising pitavastatine
|
|
JP6280554B2
(ja)
|
2012-09-28 |
2018-02-14 |
メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． |
Ｅｒｋ阻害剤である新規化合物
|
|
DK2925888T3
(en)
|
2012-11-28 |
2017-12-18 |
Merck Sharp & Dohme |
COMPOSITIONS AND METHODS OF CANCER TREATMENT
|
|
JP6387013B2
(ja)
|
2012-12-20 |
2018-09-12 |
メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． |
Ｈｄｍ２阻害薬としての置換されたイミダゾピリジン類
|
|
US9540377B2
(en)
|
2013-01-30 |
2017-01-10 |
Merck Sharp & Dohme Corp. |
2,6,7,8 substituted purines as HDM2 inhibitors
|
|
EP2976062B1
(en)
|
2013-03-21 |
2021-11-03 |
Eupraxia Pharmaceuticals USA LLC |
Injectable sustained release composition and method of using the same for treating inflammation in joints and pain associated therewith
|
|
CN104069502B
(zh)
*
|
2013-03-29 |
2018-02-16 |
北京罗诺强施医药技术研发中心有限公司 |
复合骨架材料及其药物组合物
|
|
RO129060B1
(ro)
*
|
2013-04-25 |
2014-11-28 |
Antibiotice S.A. |
Compoziţie farmaceutică stabilă cu rosuvastatină calcică amorfă
|
|
KR101597004B1
(ko)
|
2013-07-25 |
2016-02-23 |
씨제이헬스케어 주식회사 |
서방형 메트포르민과 속방형 HMG-CoA 환원효소 억제제를 포함하는 복합제제
|
|
US20160194368A1
(en)
|
2013-09-03 |
2016-07-07 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
|
WO2015051479A1
(en)
|
2013-10-08 |
2015-04-16 |
Merck Sharp & Dohme Corp. |
Cathepsin cysteine protease inhibitors
|
|
EP3055314B1
(en)
|
2013-10-08 |
2018-09-12 |
Merck Sharp & Dohme Corp. |
Cathepsin cysteine protease inhibitors
|
|
GB201319791D0
(en)
*
|
2013-11-08 |
2013-12-25 |
Sigmoid Pharma Ltd |
Formulations
|
|
US10441567B2
(en)
|
2014-01-17 |
2019-10-15 |
Ligand Pharmaceuticals Incorporated |
Methods and compositions for modulating hormone levels
|
|
WO2015120580A1
(en)
|
2014-02-11 |
2015-08-20 |
Merck Sharp & Dohme Corp. |
Cathepsin cysteine protease inhibitors
|
|
WO2015185240A1
(en)
|
2014-06-04 |
2015-12-10 |
Sigma-Tau Industrire Farmaceutiche Riunite S.P.A. |
Compositions containing simvastatin in omega-3 polyunsaturated fatty acids
|
|
JO3589B1
(ar)
|
2014-08-06 |
2020-07-05 |
Novartis Ag |
مثبطات كيناز البروتين c وطرق استخداماتها
|
|
CN107072997A
(zh)
|
2014-11-11 |
2017-08-18 |
盐野义制药株式会社 |
含有对光不稳定的药物的多层片剂
|
|
US11351124B2
(en)
|
2015-10-27 |
2022-06-07 |
Eupraxia Pharmaceuticals Inc. |
Sustained release of formulations of local anesthetics
|
|
EP3525785A4
(en)
|
2016-10-12 |
2020-03-25 |
Merck Sharp & Dohme Corp. |
KDM5 INHIBITORS
|
|
RU2648445C1
(ru)
*
|
2016-11-03 |
2018-03-26 |
Светлана Асылхановна Астафьева |
6-(3,3- диметил-3,4-дигидроизохинолин-1-ил) аминогексановая кислота и фармацевтическая композиция на ёе основе, обладающие анальгетической активностью
|
|
EP3706742B1
(en)
|
2017-11-08 |
2023-03-15 |
Merck Sharp & Dohme LLC |
Prmt5 inhibitors
|
|
US11098059B2
(en)
|
2017-11-08 |
2021-08-24 |
Merck Sharp & Dohme Corp. |
PRMT5 inhibitors
|
|
KR101954568B1
(ko)
*
|
2018-01-22 |
2019-03-05 |
한미약품 주식회사 |
오메가-3 지방산 또는 이의 에스테르 및 하이드록시메틸글루타닐 코엔자임에이 환원효소 억제제를 포함하는 경구용 복합 제제
|
|
WO2020033284A1
(en)
|
2018-08-07 |
2020-02-13 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
|
JP7446282B2
(ja)
|
2018-08-07 |
2024-03-08 |
メルク・シャープ・アンド・ドーム・エルエルシー |
Ｐｒｍｔ５阻害剤
|
|
EP3833668B1
(en)
|
2018-08-07 |
2025-03-19 |
Merck Sharp & Dohme LLC |
Prmt5 inhibitors
|
|
CA3160153A1
(en)
|
2019-12-17 |
2021-06-24 |
Michelle Machacek |
Prmt5 inhibitors
|
|
WO2024180169A1
(en)
|
2023-03-02 |
2024-09-06 |
Carcimun Biotech Gmbh |
Means and methods for diagnosing cancer and/or an acute inflammatory disease
|